DD208615A5 - Verfahren zur herstellung von substituierten 4,5-dihydro-6-(substituierten)-phenyl-3(2h)-pyridazinon- und 6-(substituierten)phenyl-3(2h)-pyridazinon-verbindungen - Google Patents

Verfahren zur herstellung von substituierten 4,5-dihydro-6-(substituierten)-phenyl-3(2h)-pyridazinon- und 6-(substituierten)phenyl-3(2h)-pyridazinon-verbindungen Download PDF

Info

Publication number: DD208615A5
Authority: DD; German Democratic Republic
Prior art keywords: substituted; phenyl; pyridazinone; dihydro; imidazol
Prior art date: 1981-09-17

Application number

DD82243270A

Other languages

German (de)

English (en)

Inventor

Ila Sircar

James A Bristol

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-09-17

Filing date

1982-09-15

Publication date

1984-04-04

1981-09-17 Priority claimed from US06/302,181 external-priority patent/US4353905A/en

1982-09-15 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1984-04-04 Publication of DD208615A5 publication Critical patent/DD208615A5/de

Links

-1 4,5-DIHYDRO-6- (SUBSTITUTED) -PHENYL-3 (2H) -PYRIDAZINONE Chemical class 0.000 title claims abstract description 59
238000004519 manufacturing process Methods 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 32
150000003839 salts Chemical class 0.000 claims abstract description 18
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
239000001257 hydrogen Substances 0.000 claims abstract description 5
150000002429 hydrazines Chemical class 0.000 claims abstract description 3
238000000034 method Methods 0.000 claims description 24
125000000217 alkyl group Chemical group 0.000 claims description 18
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
230000008569 process Effects 0.000 claims description 7
125000005843 halogen group Chemical group 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 3
125000002883 imidazolyl group Chemical group 0.000 claims description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
230000036772 blood pressure Effects 0.000 abstract description 14
239000000496 cardiotonic agent Substances 0.000 abstract description 7
230000003177 cardiotonic effect Effects 0.000 abstract description 6
239000002220 antihypertensive agent Substances 0.000 abstract description 5
229940030600 antihypertensive agent Drugs 0.000 abstract description 3
230000002107 myocardial effect Effects 0.000 abstract description 3
125000000623 heterocyclic group Chemical group 0.000 abstract 1
238000011699 spontaneously hypertensive rat Methods 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 47
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
239000000243 solution Substances 0.000 description 44
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
239000000203 mixture Substances 0.000 description 19
229960000583 acetic acid Drugs 0.000 description 16
239000002253 acid Substances 0.000 description 15
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 15
239000007787 solid Substances 0.000 description 14
238000004458 analytical method Methods 0.000 description 13
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 11
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 11
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 10
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 10
229910052794 bromium Inorganic materials 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
239000000725 suspension Substances 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 7
238000003756 stirring Methods 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
239000000047 product Substances 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 5
241001631457 Cannula Species 0.000 description 5
210000000709 aorta Anatomy 0.000 description 5
239000012458 free base Substances 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
210000004165 myocardium Anatomy 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
238000010998 test method Methods 0.000 description 5
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000003701 inert diluent Substances 0.000 description 4
229960001412 pentobarbital Drugs 0.000 description 4
238000010992 reflux Methods 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
239000012043 crude product Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 2
125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 description 2
GOAZSGLSVJVOLX-UHFFFAOYSA-N 3-(4-aminophenyl)-1h-pyridazin-6-one Chemical compound C1=CC(N)=CC=C1C1=NNC(=O)C=C1 GOAZSGLSVJVOLX-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000013480 data collection Methods 0.000 description 2
238000006356 dehydrogenation reaction Methods 0.000 description 2
230000035487 diastolic blood pressure Effects 0.000 description 2
230000003205 diastolic effect Effects 0.000 description 2
IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
150000002540 isothiocyanates Chemical class 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000000541 pulsatile effect Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
QAXBVGVYDCAVLV-UHFFFAOYSA-N tiletamine Chemical compound C=1C=CSC=1C1(NCC)CCCCC1=O QAXBVGVYDCAVLV-UHFFFAOYSA-N 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical compound CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 description 1
GFISDBXSWQMOND-UHFFFAOYSA-N 2,5-dimethoxyoxolane Chemical compound COC1CCC(OC)O1 GFISDBXSWQMOND-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
BFOMTEBFEFQJHY-UHFFFAOYSA-N 2-phenylpyridazin-3-one Chemical compound O=C1C=CC=NN1C1=CC=CC=C1 BFOMTEBFEFQJHY-UHFFFAOYSA-N 0.000 description 1
XMTUHSIIBGFSTQ-UHFFFAOYSA-N 3-(4-aminophenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(N)=CC=C1C1=NNC(=O)CC1 XMTUHSIIBGFSTQ-UHFFFAOYSA-N 0.000 description 1
ZCINDVVYYCIFLX-UHFFFAOYSA-N 3-[2-(2-chloroethoxy)phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound ClCCOC1=CC=CC=C1C1=NNC(=O)CC1 ZCINDVVYYCIFLX-UHFFFAOYSA-N 0.000 description 1
VNDXKQDZROWOTL-UHFFFAOYSA-N 4-oxo-4-[4-(1,2,4-triazol-1-yl)phenyl]butanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1N1N=CN=C1 VNDXKQDZROWOTL-UHFFFAOYSA-N 0.000 description 1
ONMOULMPIIOVTQ-UHFFFAOYSA-N 98-47-5 Chemical compound OS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 ONMOULMPIIOVTQ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
YQPVINQQPKLDEE-UHFFFAOYSA-N O=C1N(C2=CC=CC=C2N2C=NC=C2)N=CC=C1 Chemical compound O=C1N(C2=CC=CC=C2N2C=NC=C2)N=CC=C1 YQPVINQQPKLDEE-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004185 Penicillin G procaine Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000009471 action Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000010951 brass Substances 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
239000001582 butter acid Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
WQPDQJCBHQPNCZ-UHFFFAOYSA-N cyclohexa-2,4-dien-1-one Chemical compound O=C1CC=CC=C1 WQPDQJCBHQPNCZ-UHFFFAOYSA-N 0.000 description 1
238000013481 data capture Methods 0.000 description 1
238000007269 dehydrobromination reaction Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229910003480 inorganic solid Inorganic materials 0.000 description 1
230000000297 inotrophic effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
WPPKTHGCNGFZGD-UHFFFAOYSA-N methyl 3-(3-imidazol-1-ylphenyl)-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1=CC=CC(N2C=NC=C2)=C1 WPPKTHGCNGFZGD-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
229910000510 noble metal Inorganic materials 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000033116 oxidation-reduction process Effects 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
235000019370 penicillin G procaine Nutrition 0.000 description 1
229940056362 penicillin g procaine Drugs 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035485 pulse pressure Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000007655 standard test method Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960004523 tiletamine Drugs 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D521/00—Heterocyclic compounds containing unspecified hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

DD82243270A 1981-09-17 1982-09-15 Verfahren zur herstellung von substituierten 4,5-dihydro-6-(substituierten)-phenyl-3(2h)-pyridazinon- und 6-(substituierten)phenyl-3(2h)-pyridazinon-verbindungen DD208615A5 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US06/302,181 US4353905A (en)	1981-09-17	1981-09-17	Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
US40248882A	1982-07-27	1982-07-27
US40797382A	1982-08-13	1982-08-13

Publications (1)

Publication Number	Publication Date
DD208615A5 true DD208615A5 (de)	1984-04-04

Family

ID=27404868

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD82243270A DD208615A5 (de)	1981-09-17	1982-09-15	Verfahren zur herstellung von substituierten 4,5-dihydro-6-(substituierten)-phenyl-3(2h)-pyridazinon- und 6-(substituierten)phenyl-3(2h)-pyridazinon-verbindungen

Country Status (17)

Country	Link
EP (1)	EP0075436B1 (da)
KR (1)	KR880001623B1 (da)
AT (1)	ATE18909T1 (da)
AU (1)	AU563448B2 (da)
CA (1)	CA1190548A (da)
DD (1)	DD208615A5 (da)
DE (1)	DE3270274D1 (da)
DK (1)	DK414482A (da)
ES (1)	ES8400414A1 (da)
FI (1)	FI76084C (da)
GR (1)	GR76999B (da)
HU (1)	HU190412B (da)
IE (1)	IE54101B1 (da)
IL (1)	IL66815A (da)
NO (1)	NO159595C (da)
NZ (1)	NZ201929A (da)
PH (1)	PH19332A (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3212304A1 (de) *	1982-04-02	1983-10-06	Nattermann A & Cie	Imidazolylphenyl-tetrahydropyridazine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3241102A1 (de) *	1982-11-06	1984-05-10	A. Nattermann & Cie GmbH, 5000 Köln	Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
GB8310435D0 (en) *	1983-04-18	1983-05-25	Fujisawa Pharmaceutical Co	Triazine derivatives
DE3321012A1 (de) *	1983-06-10	1984-12-13	A. Nattermann & Cie GmbH, 5000 Köln	Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung
US4599332A (en) *	1983-12-07	1986-07-08	Warner-Lambert Company	4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]-ethenyl]-3(2H)-pyridazinones and related compounds
DE3401911A1 (de) *	1984-01-20	1985-08-01	A. Nattermann & Cie GmbH, 5000 Köln	Substituierte 4,5-dihydro-6-vinyl-3(2h)-pyridazinone und 6-vinyl-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung
DE3407509A1 (de) *	1984-03-01	1985-09-05	A. Nattermann & Cie GmbH, 5000 Köln	Neue arzneimittelkombination zur behandlung von bluthochdruck und thromboembolischen erkrankungen
US4584299A (en) *	1984-05-21	1986-04-22	Warner-Lambert Company	Method of treating heart failure and medicaments therefor
DE3425632A1 (de) *	1984-07-12	1986-01-16	Basf Ag, 6700 Ludwigshafen	(pyrrol-1-yl)-phenyl-dihydropyridazinone, ihre herstellung und verwendung
JPS61158969A (ja) *	1984-12-24	1986-07-18	ワーナー‐ランバート・コンパニー	４，５‐ジヒドロ‐４，４‐ジアルキル‐６‐（置換）フエニル‐３（２ｈ）‐ピリダジノン類
GB8502267D0 (en) *	1985-01-30	1985-02-27	Pfizer Ltd	Quinolone inotropic agents
IL79280A (en) *	1985-07-05	1990-07-12	Smith Kline French Lab	4-(6-oxo-dihydro or tetrahydropyridazin-3-yl)benzene derivatives,their preparation and pharmaceutical compositions containing them
US4783463A (en) *	1985-10-23	1988-11-08	Rorer Pharmaceutical Corporation	Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
US4826835A (en) *	1985-10-23	1989-05-02	Rorer Pharmaceutical Corporation	Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
DE3600275A1 (de) *	1986-01-08	1987-07-09	Basf Ag	Substituierte pyrrol-1-ylphenyldihydropyridazinone, ihre herstellung und verwendung
DE3626865A1 (de) *	1986-08-08	1988-02-11	Boehringer Mannheim Gmbh	Neue pyridazinon-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4888169A (en) *	1986-10-14	1989-12-19	Norden Laboratories, Inc.	Bordetella Bronchiseptica vaccine
US4970210A (en) *	1987-07-17	1990-11-13	Abbott Laboratories	Triazinone lipoxygenase compounds
EP0326307B1 (en) *	1988-01-23	1994-08-17	Kyowa Hakko Kogyo Co., Ltd.	Novel pyridazinone derivatives and pharmaceutical preparations containing them
DE3804490A1 (de) *	1988-02-12	1989-08-24	Heumann Pharma Gmbh & Co	Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3814057A1 (de) *	1988-04-26	1989-11-09	Heumann Pharma Gmbh & Co	6-oxo-pyridazinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3826855A1 (de) *	1988-08-06	1990-02-15	Cassella Ag	4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung
DE3913597A1 (de) *	1989-04-25	1990-11-08	Heumann Pharma Gmbh & Co	Diazinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DK40192D0 (da) *	1992-03-26	1992-03-26	Neurosearch As	Imidazolforbindelser, deres fremstilling og anvendelse
US7462613B2 (en)	2002-11-19	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7309701B2 (en)	2002-11-19	2007-12-18	Sanofi-Aventis Deutschland Gmbh	Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
EP1598348A1 (en)	2004-05-18	2005-11-23	Aventis Pharma Deutschland GmbH	Novel pyridazinone derivatives as inhibitors of CDK2
EP1604988A1 (en)	2004-05-18	2005-12-14	Sanofi-Aventis Deutschland GmbH	Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
TWI375669B (en)	2006-03-17	2012-11-01	Sumitomo Chemical Co	Pyridazinone compound and use thereof
HRP20130044T1 (hr)	2006-07-25	2013-02-28	Cephalon, Inc.	Derivati piridizinona
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (da)	2011-03-01	2018-04-16	Synergy Pharmaceuticals Inc	Fremgangsmåde til fremstilling af guanylat-cyclase-c-agonister
WO2014131024A2 (en)	2013-02-25	2014-08-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt)	2013-06-05	2017-08-29	Synergy Pharmaceuticals Inc	Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
AU2014305843B2 (en)	2013-08-09	2019-08-29	Ardelyx, Inc.	Compounds and methods for inhibiting phosphate transport
EP4706758A3 (en)	2019-05-21	2026-05-06	Ardelyx, Inc.	Methods for inhibiting phosphate transport

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1383906A (en) *	1971-02-22	1974-02-12	Bdh Pharmaceuticals Ltd	Pyridazinones
BE790106A (fr) *	1971-10-14	1973-04-13	Basf Ag	Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
DE3130251A1 (de) *	1981-07-31	1983-02-17	A. Nattermann & Cie GmbH, 5000 Köln	6-(4-((omega)-(1-imidazolyl)-alkyl)-phenyl)-3-oxo -2,3,4,5-tetrahydro-pyridazine und deren saeureadditionssalze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate

1982
- 1982-09-14 HU HU822925A patent/HU190412B/hu not_active IP Right Cessation
- 1982-09-15 AU AU88409/82A patent/AU563448B2/en not_active Ceased
- 1982-09-15 NO NO82823128A patent/NO159595C/no unknown
- 1982-09-15 CA CA000411513A patent/CA1190548A/en not_active Expired
- 1982-09-15 ES ES515743A patent/ES8400414A1/es not_active Expired
- 1982-09-15 AT AT82304855T patent/ATE18909T1/de not_active IP Right Cessation
- 1982-09-15 KR KR8204179A patent/KR880001623B1/ko not_active Expired
- 1982-09-15 DD DD82243270A patent/DD208615A5/de not_active IP Right Cessation
- 1982-09-15 PH PH27877A patent/PH19332A/en unknown
- 1982-09-15 EP EP82304855A patent/EP0075436B1/en not_active Expired
- 1982-09-15 IE IE2250/82A patent/IE54101B1/en unknown
- 1982-09-15 NZ NZ201929A patent/NZ201929A/en unknown
- 1982-09-15 FI FI823184A patent/FI76084C/fi not_active IP Right Cessation
- 1982-09-15 DE DE8282304855T patent/DE3270274D1/de not_active Expired
- 1982-09-15 GR GR69283A patent/GR76999B/el unknown
- 1982-09-16 IL IL66815A patent/IL66815A/xx unknown
- 1982-09-16 DK DK414482A patent/DK414482A/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0075436B1 (en)	1986-04-02
FI823184L (fi)	1983-03-18
FI823184A0 (fi)	1982-09-15
HU190412B (en)	1986-09-29
FI76084B (fi)	1988-05-31
ATE18909T1 (de)	1986-04-15
IL66815A (en)	1986-02-28
FI76084C (fi)	1988-09-09
CA1190548A (en)	1985-07-16
IL66815A0 (en)	1982-12-31
IE54101B1 (en)	1989-06-21
DE3270274D1 (en)	1986-05-07
EP0075436A1 (en)	1983-03-30
KR880001623B1 (ko)	1988-09-02
AU8840982A (en)	1983-03-24
NO823128L (no)	1983-03-18
ES515743A0 (es)	1983-10-16
AU563448B2 (en)	1987-07-09
NO159595B (no)	1988-10-10
NO159595C (no)	1989-01-18
GR76999B (da)	1984-09-04
PH19332A (en)	1986-03-20
ES8400414A1 (es)	1983-10-16
KR840001570A (ko)	1984-05-07
IE822250L (en)	1983-03-17
NZ201929A (en)	1985-11-08
DK414482A (da)	1983-03-18

Legal Events

Date	Code	Title	Description
1995-05-11	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD208615A5 (de)	1984-04-04	Verfahren zur herstellung von substituierten 4,5-dihydro-6-(substituierten)-phenyl-3(2h)-pyridazinon- und 6-(substituierten)phenyl-3(2h)-pyridazinon-verbindungen
US4353905A (en)	1982-10-12	Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
EP0497852B1 (de)	1995-12-20	Bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4397854A (en)	1983-08-09	Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
EP0196005B1 (de)	1989-12-20	Pyridazinone, ihre Herstellung und diese Verbindungen enthaltende Arzneimittel
US4734415A (en)	1988-03-29	Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
US4602019A (en)	1986-07-22	Indeno[1,2-c]pyridazin-3-one derivatives useful as cardiotonic and antihypertensive agents
DE69109090T2 (de)	1995-09-14	2-substituierte 4,5-diphenylimidazole.
DE3789754T2 (de)	1994-12-15	Die Bildung von Lipid-peroxiden hemmende Zusammenstzung und dafür geeignete Verbindungen.
US4503061A (en)	1985-03-05	Substituted phenyl-pyridinones as cardiotonic agents
DE2427943A1 (de)	1976-01-08	Neue benzimidazole
EP0145019B1 (en)	1990-11-07	Pyridazinone derivatives and salts thereof
EP0102227B1 (en)	1989-05-03	2(1h)-pyridinones, useful as cardiotonic agents, and their production
US4847251A (en)	1989-07-11	Pyridazinone derivatives, and pharmaceutical compositions containing them
EP0071102A1 (de)	1983-02-09	Neue Benztriazole, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0026321B1 (de)	1983-02-09	6-Imidazol-1-yl-3-hydrazino-pyridazine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4717730A (en)	1988-01-05	4,5-dihydro-6-(substituted)phenyl-5-methyl-3-(2H)-pyridazinones and pharmaceutical compositions containing the compounds as active components
DE69325934T2 (de)	2000-01-13	Substituierte Triazole als Angiotensin-II-Inhibitoren
US4971968A (en)	1990-11-20	Pyridazinone derivatives and salts thereof
EP0018542B1 (de)	1983-03-02	Phenothiazinderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
DE3605676A1 (de)	1986-09-18	Ergolinderivate und deren saeureadditionssalze
JPS63501218A (ja)	1988-05-12	ピリジル−ピリダジノン化合物及びピリジル−ピラゾリノン化合物並びにそれらの充血性心不全治療上の用途
US4607037A (en)	1986-08-19	Cardiotonic 2(1H)-pyridinones
WO1991002730A1 (de)	1991-03-07	Neue substituierte heterocyclische fünfringe, ihre herstellung und verwendung
AT358033B (de)	1980-08-11	Verfahren zur herstellung neuer imidazol- derivate und ihrer salze